Epic Sciences

Epic Sciences is a genetic testing company that develops and markets diagnostic tests to support therapy selection and monitor disease progression for patients with prostate or breast cancer. These services are available to pharmaceutical companies and cancer centers across the world.

As of April 2023, the firm had two diagnostic tests: DefineMBC and AR-V7. Its DefineMBC test combines circulating tumor cells analysis together with single-cell whole-genome sequencing and cell-free DNA sequencing into a single blood draw. This test is used to profile metastatic (late stage) breast cancer when a tissue biopsy is unavailable. Its AR-V7 liquid biopsy test identifies patients with metastatic prostate cancer who are likely to be resistant to androgen receptor-directed therapies, which are a gold standard for treating prostate cancer. According to Epic Sciences, this is the first and only Medicare-covered liquid biopsy for metastatic prostate cancer that has been clinically validated.

Key customers and partnerships

The firm operates a B2B2C model and is available to patients via healthcare providers. It also offers cancer profiling services to pharmaceutical companies, supporting them with the drug development process, including biomarker validation, patient selection, and companion diagnostic development. As of April 2023, Epic Sciences had partnered with 68 pharmaceutical companies.

  Funding and Financials

I n April 2023 , the company raised USD 24 million in a Series G funding round led by Deerfield Management and Arsenal Capital Partners. The funds were used to commercialize the DefineMBC tests and expand its market-facing departments including sales, product marketing, medical affairs, and payer markets.